Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR1 | P21554 | 6/20 | 0.47 |
| ▸ | CNR2 | P34972 | 2/20 | 0.40 |
| ▸ | F2 | P00734 | 1/20 | 0.37 |
| ▸ | UTS2R | Q9UKP6 | 3/20 | 0.36 |
| ▸ | AVPR1A | P37288 | 1/20 | 0.36 |
| ▸ | DPP4 | P27487 | 3/20 | 0.36 |
| ▸ | DPP8 | Q6V1X1 | 2/20 | 0.36 |
| ▸ | DPP7 | Q9UHL4 | 2/20 | 0.36 |
| ▸ | FAP | Q12884 | 1/20 | 0.36 |
| ▸ | DPP9 | Q86TI2 | 1/20 | 0.36 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22663739 | 0.91 | CNR1 (0.49) | CNR1CNR2F2UTS2RAVPR1A | |
| SCHEMBL24067389 | 0.84 | CNR1 (0.44) | CNR1CNR2 | |
| SCHEMBL22450602 | 0.84 | CNR1 (0.44) | CNR1CNR2 | |
| SCHEMBL24067347 | 0.84 | CNR1 (0.44) | CNR1CNR2 | |
| SCHEMBL24067349 | 0.84 | CNR1 (0.43) | CNR1CNR2F2UTS2RAVPR1A | |
| SCHEMBL24067352 | 0.83 | CNR1 (0.42) | CNR1CNR2AVPR1ADPP4DPP8 | |
| SCHEMBL24067396 | 0.82 | KRAS (0.46) | CNR1CNR2F2UTS2RAVPR1A | |
| SCHEMBL24067461 | 0.81 | CNR1 (0.50) | CNR1CNR2DPP4DPP8DPP7 | |
| SCHEMBL24067300 | 0.80 | IL1B (0.49) | CNR1CNR2AVPR1A | |
| SCHEMBL24488621 | 0.80 | CNR1 (0.38) | CNR1CNR2F2UTS2RDPP4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220175917-A1 | COMBINATION OF IAP INHIBITOR AND IMMUNE CHECKPOINT INHIBITOR | CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD. (CN) | 2022-06-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220175917-A1 | COMBINATION OF IAP INHIBITOR AND IMMUNE CHECKPOINT INHIBITOR | BIRC5, XIAP, BIRC2 | CNR1 4767/4885CNR2 4858/4885F2 4851/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.